Articles published by RenovoRx, Inc.
RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting
March 28, 2025
From RenovoRx, Inc.
Via Business Wire
Tickers
RNXT
RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET
March 20, 2025
From RenovoRx, Inc.
Via Business Wire
Tickers
RNXT
RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025
March 19, 2025
From RenovoRx, Inc.
Via Business Wire
Tickers
RNXT

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders
February 26, 2025
From RenovoRx, Inc.
Via Business Wire
Tickers
RNXT

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock
February 11, 2025
From RenovoRx, Inc.
Via Business Wire
Tickers
RNXT

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock
February 06, 2025
From RenovoRx, Inc.
Via Business Wire
Tickers
RNXT

RenovoRx Announces Proposed Public Offering
February 06, 2025
From RenovoRx, Inc.
Via Business Wire
Tickers
RNXT

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025
January 27, 2025
From RenovoRx, Inc.
Via Business Wire
Tickers
RNXT

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025
January 08, 2025
From RenovoRx, Inc.
Via Business Wire
Tickers
RNXT

RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform
December 30, 2024
From RenovoRx, Inc.
Via Business Wire
Tickers
RNXT

RenovoRx CEO Issues Update Letter to Shareholders
May 30, 2024
From RenovoRx, Inc.
Via Business Wire
Tickers
RNXT



RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024
May 02, 2024
From RenovoRx, Inc.
Via Business Wire
Tickers
RNXT



RenovoRx Announces $11.1 Million at Market Private Placement
April 08, 2024
From RenovoRx, Inc.
Via Business Wire
Tickers
RNXT

RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
April 05, 2024
From RenovoRx, Inc.
Via Business Wire
Tickers
RNXT


RenovoRx Highlights Key Leadership Promotions
March 08, 2024
From RenovoRx, Inc.
Via Business Wire
Tickers
RNXT

RenovoRx CEO Issues Letter to Shareholders
February 06, 2024
From RenovoRx, Inc.
Via Business Wire
Tickers
RNXT

RenovoRx Closes $6.1 Million Private Placement
January 29, 2024
From RenovoRx, Inc.
Via Business Wire
Tickers
RNXT


RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
December 19, 2023
From RenovoRx, Inc.
Via Business Wire
Tickers
RNXT

RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform
December 13, 2023
From RenovoRx, Inc.
Via Business Wire
Tickers
RNXT

RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.
November 16, 2023
From RenovoRx, Inc.
Via Business Wire
Tickers
RNXT


RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023
October 02, 2023
From RenovoRx, Inc.
Via Business Wire
Tickers
RNXT

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.